지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이 논문의 연구 히스토리 (2)
- 이 논문의 후속연구가 궁금하신가요?
- 연관 학술논문 또는 학술발표를 통해 보다 발전된 연구결과를 확인하실 수 있습니다.
- 이 논문의 연구 히스토리 확인하기
초록· 키워드
오류제보하기
Objectives: This study aimed to evaluate the effects of microparticles of Socheongryong-tang (SCRT) on chronic obstructive pulmonary disease (COPD) in a mouse model.
Methods: The inhalable microparticles containing SCRT were produced by spray-drying with leucine as an excipient, and evaluated with respect to the aerodynamic properties of the powder by Andersen cascade impactor (ACI). Its equivalence to SCRT extract was evaluated using lipopolysaccharide (LPS) and a cigarette-smoking (CS)-induced murine COPD model.
Results: SCRT microparticles provided desirable aerodynamic properties (fine particle fraction of 49.6±5.5% and mass median aerodynamic diameter of 4.8±0.3μm). SCRT microparticles did not show mortality or clinical signs over 14 days. Also there were no significant differences in body weight, organ weights or serum chemical parameters between SCRT microparticle-treated and non-treated groups. After 14 days the platelet count significantly increased compared with the non-treated group, but the values were within the normal range. Inhalation of SCRT microparticles decreased the rate of neutrophils in blood, granulocytes in peripheral blood mononuclear cells (PBMC) and bronchoalveolar lavage fluid (BALF) and level of TNF-α and IL-6 in BALF on COPD mouse model induced by LPS plus CS. This effect was verified by histological findings including immunofluorescence staining of elastin, collagen, and caspase 3 protein in lung tissue.
Conclusions: These data demonstrate that SCRT microparticles are equivalent to SCRT extract in pharmaceutical properties for COPD. This study suggests that SCRT microparticles would be a potential agent of inhalation therapy for the treatment of COPD.
Methods: The inhalable microparticles containing SCRT were produced by spray-drying with leucine as an excipient, and evaluated with respect to the aerodynamic properties of the powder by Andersen cascade impactor (ACI). Its equivalence to SCRT extract was evaluated using lipopolysaccharide (LPS) and a cigarette-smoking (CS)-induced murine COPD model.
Results: SCRT microparticles provided desirable aerodynamic properties (fine particle fraction of 49.6±5.5% and mass median aerodynamic diameter of 4.8±0.3μm). SCRT microparticles did not show mortality or clinical signs over 14 days. Also there were no significant differences in body weight, organ weights or serum chemical parameters between SCRT microparticle-treated and non-treated groups. After 14 days the platelet count significantly increased compared with the non-treated group, but the values were within the normal range. Inhalation of SCRT microparticles decreased the rate of neutrophils in blood, granulocytes in peripheral blood mononuclear cells (PBMC) and bronchoalveolar lavage fluid (BALF) and level of TNF-α and IL-6 in BALF on COPD mouse model induced by LPS plus CS. This effect was verified by histological findings including immunofluorescence staining of elastin, collagen, and caspase 3 protein in lung tissue.
Conclusions: These data demonstrate that SCRT microparticles are equivalent to SCRT extract in pharmaceutical properties for COPD. This study suggests that SCRT microparticles would be a potential agent of inhalation therapy for the treatment of COPD.
목차
서론
재료와 방법
결과
고찰
결론
참고문헌
참고문헌 (40)
참고문헌 신청
1. [인터넷자원] - Statistics Korea / / Cause of death statistics 2011. 2012;[2screens]
2. [학술지(정기간행물)] - Mannino DM / 2006 / Changing the burden ofCOPD mortality / Int J Chron Obstruct Pulmon Dis 1 (3) : 219 ~ 233
3. [학술지(정기간행물)] - Mannino DM / 2002 / COPD: epidemiology, prevalence, morbidityand mortality, and disease heterogeneity / Chest 121 : 121S ~ 126S
4. [학술지(정기간행물)] - Celli BR / 2004 / Standards for the diagnosis andtreatment of patients with COPD: a summary of theATS/ERS position paper / Eur Respir J 23 (6) : 932 ~ 946
5. [학술지(정기간행물)] - Barnes PJ / 2004 / Prospects for new drugs forchronic obstructive pulmonary disease / Lancet 364 (9438) : 985 ~ 996
2. [학술지(정기간행물)] - Mannino DM / 2006 / Changing the burden ofCOPD mortality / Int J Chron Obstruct Pulmon Dis 1 (3) : 219 ~ 233
3. [학술지(정기간행물)] - Mannino DM / 2002 / COPD: epidemiology, prevalence, morbidityand mortality, and disease heterogeneity / Chest 121 : 121S ~ 126S
4. [학술지(정기간행물)] - Celli BR / 2004 / Standards for the diagnosis andtreatment of patients with COPD: a summary of theATS/ERS position paper / Eur Respir J 23 (6) : 932 ~ 946
5. [학술지(정기간행물)] - Barnes PJ / 2004 / Prospects for new drugs forchronic obstructive pulmonary disease / Lancet 364 (9438) : 985 ~ 996
이 논문의 저자 정보
이 논문과 함께 이용한 논문
최근 본 자료
댓글(0)
0